Complement C1q (C1q Complement)

A subcomponent of complement C1, composed of six copies of three polypeptide chains (A, B, and C), each encoded by a separate gene (C1QA; C1QB; C1QC). This complex is arranged in nine subunits (six disulfide-linked dimers of A and B, and three disulfide-linked homodimers of C). C1q has binding sites for antibodies (the heavy chain of IMMUNOGLOBULIN G or IMMUNOGLOBULIN M). The interaction of C1q and immunoglobulin activates the two proenzymes COMPLEMENT C1R and COMPLEMENT C1S, thus initiating the cascade of COMPLEMENT ACTIVATION via the CLASSICAL COMPLEMENT PATHWAY.

Also Known As:

Networked: 221 relevant articles (3 outcomes, 22 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Trendelenburg, Marten: 9 articles (01/2021 - 11/2005)
2.	Severance, Emily G: 4 articles (11/2016 - 12/2012)
3.	Yolken, Robert H: 4 articles (11/2016 - 12/2012)
4.	Sumbul, Hilmi Erdem: 3 articles (01/2022 - 12/2020)
5.	Wang, Qin: 3 articles (01/2022 - 10/2020)
6.	Gressitt, Kristin L: 3 articles (11/2016 - 12/2012)
7.	Lu, Jinhua: 3 articles (09/2015 - 08/2010)
8.	Bigler, Cornelia: 3 articles (04/2011 - 09/2009)
9.	Danner, Doris: 3 articles (04/2011 - 09/2008)
10.	Schaller, Monica: 3 articles (04/2011 - 09/2009)

Related Diseases

1.	Atherosclerosis 01/01/2021 - "Background: Complement C1q plays a dual role in the atherosclerosis. " 01/01/2020 - "Complement C1q is an important initial component of the classical complement pathway and closely related to many chronic inflammatory diseases, including atherosclerosis (AS). " 11/01/2009 - "Molecular-genetic causation studies in mouse models of advanced atherosclerosis have provided evidence that several molecules known to be involved in efferocytosis, including TG2, MFG-E8, complement C1q, Mertk, lysoPC, and Fas, play important roles in the clearance of apoptotic cells in advanced plaques. " 01/01/2022 - "Involvement of enhanced expression of classical complement C1q in atherosclerosis progression and plaque instability: C1q as an indicator of clinical outcome." 01/01/2007 - "Complement C1q reduces early atherosclerosis in low-density lipoprotein receptor-deficient mice."
2.	Cognitive Dysfunction 01/01/2021 - "Microglia-selective genetic deletion of CNS complement C1q ameliorates radiation-induced cognitive impairments, synaptic loss, and neuroinflammation, highlighting the potential for C1q as a novel therapeutic target.See" 10/01/2023 - "Complement C1q drives microglia-dependent synaptic loss and cognitive impairments in a mouse model of lipopolysaccharide-induced neuroinflammation." 02/17/2020 - "The study evaluated levels of both CHI3L1 and CHI3L2, NPTX2, ionized calcium-binding adapter molecule 1 (Iba1), complement component 1q (C1q), glial fibrillary acidic protein (GFAP), and CD44, in the frontal cortex of people who died with an antemortem clinical diagnosis of no cognitive impairment (NCI), mild cognitive impairment (MCI), mild/moderate AD (mAD), and severe AD (sAD) using immunoblot and immunohistochemical techniques. "
3.	Lung Neoplasms (Lung Cancer) 01/01/2021 - "A Preliminary Study of the Complement Component 1q Levels in Predicting the Efficacy of Combined Immunotherapy in Patients with Lung Cancer." 01/01/2021 - "To evaluate the value of serum complement component 1q (C1q) levels in predicting the efficacy of combined immunotherapy in patients with lung cancer. "
4.	Neuroinflammatory Diseases 01/01/2022 - "Complement C1q is implicated in neuroinflammation. " 01/01/2021 - "Glia-Selective Deletion of Complement C1q Prevents Radiation-Induced Cognitive Deficits and Neuroinflammation." 01/01/2021 - "Microglia-selective genetic deletion of CNS complement C1q ameliorates radiation-induced cognitive impairments, synaptic loss, and neuroinflammation, highlighting the potential for C1q as a novel therapeutic target.See" 05/01/2020 - "The complement C1q plays a critical role in microglial phagocytosis of glutamatergic synapses and in the pathogenesis of neuroinflammation in Alzheimer's disease (AD). " 08/20/2015 - "These neuropathological changes were paralleled by widespread neuroinflammation, upregulation of complement C1q, abnormalities in synaptic, axonal transport and cytoskeletal proteins, and neurodegeneration. "
5.	Type 2 Diabetes Mellitus (MODY) 01/01/2023 - "The aim of this study was to examine the association between serum complement 1q (C1q) and the associated factors of acute ischemic stroke in patients with type 2 diabetes (T2DM). " 01/01/2023 - "Association between serum complement 1q and the associated factors of acute ischemic stroke in patients with type 2 diabetes." 01/01/2015 - "The aim of this study was to evaluate the plasma concentrations of CTRP1 (complement-C1q TNF-related protein 1) in 22 patients with NAFLD, 22 patients with type 2 diabetes mellitus (T2DM), 22 patients with NAFLD+T2DM and 21 healthy controls, as well as their correlation with the level of metabolic and hepatic parameters. " 02/01/2017 - "The Circulating Levels of Complement-C1q/TNF-Related Protein 13 (CTRP13) in Patients with Type 2 Diabetes and its Association with Insulin Resistance." 01/01/2017 - "Circulating C1q complement/TNF-related protein (CTRP) 1, CTRP9, CTRP12 and CTRP13 concentrations in Type 2 diabetes mellitus: In vivo regulation by glucose."

Related Drugs and Biologics

1.	c-Mer Tyrosine Kinase
2.	Proteins (Proteins, Gene)
3.	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)
4.	Carrier Proteins (Binding Protein)
5.	Biomarkers (Surrogate Marker)
6.	Calcium
7.	Mitochondrial Proteins (Mitochondrial Protein)
8.	Insulin (Novolin)
9.	Glial Fibrillary Acidic Protein
10.	Lipocalin-2

Related Therapies and Procedures

1.	Immunotherapy
2.	Therapeutics
3.	Nephrectomy
4.	Percutaneous Coronary Intervention
5.	Immunomodulation